Creation of collective immune as the main preventive measure for the spread of the new coronavirus infection (COVID-19)
DOI:
https://doi.org/10.21638/spbu11.2022.306Abstract
Achieving the required level of herd immunity against a new coronavirus infection (COVID-19) in order to protect the population is an urgent issue in preventive and practical medicine around the world. Herd immunity is an indirect indicator of protection against COVID-19 disease and is made up of the immunity of individuals in a particular group. Epidemiological monitoring of the structure, formation, and dynamics of herd immunity will make it possible to correctly and timely adjust approaches to anti-epidemic measures, both in individual risk groups, in particular among medical workers, and in society as a whole. The required level of herd immunity against a new coronavirus infection can be achieved naturally, after a disease, or artificially, through mass immunization of the population. To date, vaccination is the safest, most effective, and most cost-effective method. Serological research methods (detection of IgG) indicate the effectiveness
of vaccination — the formation of post-vaccination immunity or a past disease. Determining the period of time at which a stable antibody titer is determined, as well as their level, is essential for predicting morbidity.
Keywords:
novel coronavirus infection, herd immunity, vaccination, antibodies, COVID-19, IgG
Downloads
Download data is not yet available.
References
Литература
Попова А. Ю., Ежлова Е. Б., Мельникова А. А., Кутырев В. В., Кожанова О. И., Черкасская Т. С., Лялина В. И., Смирнов В. С., Бугоркова С. А., Портенко С. А., Найденова Е. В., Щербакова С. А.,Ломоносова В. И., Тотолян А. А. Характеристика популяционного иммунитета к SARS-Cov-2 у жителей Саратова и Саратовской области в период пандемии COVID-19 // Проблемы особо опасных инфекций. 2020. № 4. С. 106–116.
Ashby B., Best A. Herdimmunity // Curr. Biol. 2021. Vol. 31, no. 4. P. 174–177.
Борисова А. А., Попова Н. Д., Кычкина А. И., Рожина А. А., Федулова А. Г. Эпидемиологические особенности динамики новой коронавирусной инфекции (COVID-19) в Республике Саха (Якутия) // Международный научно-исследовательский журнал. 2022. Т. 115, № 1–2. С. 84–87.
Онищенко Г. Г., Сизикова Т. Е., Лебедев В. Н., Борисевич С. В. Сравнительная характеристика вакцин против COVID-19, используемых при проведении массовой иммунизации //БИОпрепараты. Профилактика, диагностика, лечение. 2021. Т. 21, № 3. С. 158–166. https://doi.org/10.30895/2221-996X-2021-21-3-158-166
Цыганков П. В., Альникин А. Б., Кваше И. В., Шлык С. В., Харсеева Г. Г., Рябцева О. А., Тарабанова И. В. Частота выявления положительных маркеров COVID-19 у лиц с различным прививочным анамнезом // Эпидемиология и вакцинопрофилактика. 2021. Т. 20, № 3. С. 4–7.
Попова А. Ю., Ежлова Е. Б., Мельникова А. А., Башкетова Н. С., Фридман Р. К., Лялина Л. В.,Смирнов В. С., Чхинджерия И. Г., Гречанинова Т. А., Агапов К. А., Арсентьева Н. А., Баженова Н. А., Бацунов О. К., Данилова Е. М., Зуева Е. В., Комкова Д. В., Кузнецова Р. Н., Любимова Н. Е.,Маркова А. Н., Хамитова И. В., Ломоносова В. И., Ветров В. В., Миличкина А. М., Дедков В. Г.,Тотолян А. А. Популяционный иммунитет к SARS-Cov-2 среди населения Санкт-Петербурга в период эпидемии COVID-19 // Проблемы особо опасных инфекций. 2020. № 3. С. 124–130.
Годков М. А., Шустов В. В., Коршунов В. А., Степанов Ф. С., Баженов А. И. Формирование коллективного иммунитета к SARS-CoV-2 в популяции населения Москвы // Эпидемиология и вакцинопрофилактика. 2022. Т. 21. № 1. С. 81–91. https://doi.org/10.31631/2073-3046-2022-21-1-81-91
Kadkhoda K. Herd Immunity to COVID-19 // Am. J. Clin. Path. 2021. Vol. 155, no. 4. P. 471–472.
Fontanet A., Cauchemez S. COVID-19 herd immunity: Where are we? // Nat. Rev. Immunol. 2020.Vol. 20, no. 10. P. 583–584. https://doi.org/10.1038/s41577-020-00451-5
Mellet J., Pepper M. S. A COVID-19 Vaccine: Big Strides Come with Big Challenges // Vaccines (Basel).2021. Vol. 9, no. 1. P. 39. https://doi.org/10.3390/vaccines9010039
Mistry P., Barmania F., Mellet J., Peta K., Strydom A., Viljoen I. M., James W., Gordon S., Pepper M. S.SARS-CoV-2 Variants, Vaccines, and Host Immunity // Front. Immunol. 2022. No. 12. P. 809244.https://doi.org/10.3389/fimmu.2021.809244
Lea C. S., Simeonsson K., Kipp A. M., McNeill Ch., Wilcox L., Irish W., Morris H., Diaz O. M., Fallon J. T.,Roper R. L. Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months// Vaccines (Basel). 2022. Vol. 10, no. 9. P. 1532. https://doi.org/10.3390/vaccines10091532
Попова А. Ю., Ежлова Е. Б., Мельникова А. А., Патяшина М. А., Сизова Е. П., Юзлибаева Л. Р.,Лялина Л. В., Смирнов В. С., Бадамшина Г. Г., Гончарова А. В., Арбузова Т. В., Ломоносова В. И.,Тотолян А. А. Характеристика серопревалентности к SARS-Cov-2 среди населения Республики Татарстан на фоне COVID-19 // Журнал микробиологии, эпидемиологии и иммунобиологии.2020. Т. 97, № 6. С. 518–528.
Long Q. X., Liu B. Z., Deng H. J., Wu G. C., Deng K., Chen Y. K., Liao P., Qiu J. F., Lin Y., Cai X. F.,Wang D. Q., Hu Y., Ren J. H., Tang N., Xu Y. Y., Yu L. H., Mo Z., Gong F., Zhang X. L., Tian W. G., Hu L.,Zhang X. X., Xiang J. L., Du H. X., Liu H. W., Lang C. H., Luo X. H., Wu S. B., Cui X. P., Zhou Z., Zhu M. M.,Wang J., Xue C. J., Li X. F., Wang L., Li Z. J., Wang K., Niu C. C., Yang Q. J., Tang X. J., Zhang Y., Liu X. M.,Li J. J., Zhang D. C., Zhang F., Liu P., Yuan J., Li Q., Hu J. L., Chen J., Huang A. L. Antibody responses toSARS-CoV-2 in patients with COVID-19 // Nat. Med. 2020. Vol. 26, no. 6. P. 845–848.
Dan J. M., Mateus J., Kato Y., Hastie K. M., Yu E. D., Faliti C. E., Grifoni A., Ramirez S. I., Haupt S.,Crotty Sh. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection // Science.2021. Vol. 371, no. 6529. https://doi.org/10.1126/science.abf4063
Pollan M., Perez-Gjmez B., Pastor-Barriuso R., Oteo J., Hernan M. A., Perez-Olmeda M., Sanmartin J. L.,Fernandez-Garcia A., Cruz I., Fernandez de Larrea N., Molina M., Rodriguez-Cabrera F., Martin M.,Merino-Amador P., Leon Paniagua J., Munoz-Montalvo J. F., Blanco F., Yotti R. ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study // The Lancet. 2020. Vol. 396, no. 10250, pp. 535–544. https://doi.org/10.1016/S0140-6736(20)31483-5
Wajnberg A., Amanat F., Firpo A., Altman D. R., Bailey M. J., Mansour M., McMahon M., Meade P., Mendu D. R., Muellers K., Stadlbauer D., Stone K., Strohmeier S., Simon V., Aberg J., Reich D. L., Krammer F., Cordon-Cardo C. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months// Science. 2020. Vol. 370, no. 6521. P. 1227–1230. https://doi.org/10.1126/science.abd7728
Van Elslande J., Oyaert M., Ailliet S., Van Ranst M., Lorent N., Vande Weygaerde Y., Andre E., Lagrou K., Vandendriessche S., Vermeersch P. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection // J. Clin. Virol. 2021. Vol. 136. https://doi.org/10.1016/j.jcv.2021.104765
Kim P., Gordon S. M., Sheehan M. M., Rothberg M. B. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study// Clinical Infectious Diseases. 2022. Vol. 75, no. 1. P. e185–e190. https://doi.org/10.1093/cid/ciab999
Lumley S. F., O’Donnell D., Stoesser N. E., Matthews P. C., Howarth A., Hatch S. B., Marsden B. D., Cox S., James T., Warren F., Peck L. J., Ritter T. G., de Toledo Z., Warren L., Axten D., Cornall R. J., Jones E. Y., Stuart D. I., Screaton G., Ebner D., Hoosdally S., Chand M., Crook D. W., O’Donnell A. M., Conlon C. P.,Pouwels K. B., Walker A. S., Peto T. E. A., Hopkins S., Walker T. M., Jeffery K., Eyre D. W. Oxford University Hospitals Staff Testing Group. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers // N. Engl. J. Med. 2021. Vol. 384, no. 6. P. 533–540. https://doi.org/10.1056/NEJMoa2034545
Ibarrondo F. J., Fulcher J. A., Goodman-Meza D., Elliott J., Hofmann C., Hausner M. A., Ferbas K. G.,Tobin N. H., Aldrovandi G. M., Yang O. O. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19 // N. Engl. J. Med. 2020. Vol. 383, no. 11. P. 1085–1087. https://doi.org/10.1056/NEJMc2025179
Lea C. S., Simeonsson K., Kipp A. M., McNeill C., Wilcox L., Irish W., Morris H., Diaz O. M., Fallon J. T.,Roper R. L. Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months// Vaccines (Basel). 2022. Vol. 10, no. 9. P. 1532. https://doi.org/10.3390/vaccines10091532
Patel M. M., Thornburg N. J., Stubblefield W. B., Talbot H. K., Coughlin M. M., Feldstein L. R., Self W. H. Change in Antibodies to SARS-CoV-2 over 60 Days among Health Care Personnel in Nashville, Tennessee// JAMA. 2020. Vol. 324, no. 17. P. 1781–1782. https://doi.org/10.1001/jama.2020.18796
Wajnberg A., Mansour M., Leven E., Bouvier N. M., Patel G., Firpo-Betancourt A., Mendu R., Jhang J.,Arinsburg S., Gitman M., Houldsworth J., Sordillo E., Paniz-Mondolfi A., Baine I., Simon V., Aberg J.,Krammer F., Reich D., Cordon-Cardo C. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: An observational study Lancet Microbe. 2020. Vol. 1,no. 7. P. E283–E289. https://doi.org/10.1016/S2666-5247(20)30120-8
Logunov D. Y., Dolzhikova I. V., Shcheblyakov D. V., Tukhvatulin A. I., Zubkova O. V., Dzharullaeva A. S.,Kovyrshina A. V., Lubenets N. L., Grousova D. M., Erokhova A. S., Botikov A. G., Izhaeva F. M.,Popova O., Ozharovskaya T. A., Esmagambetov I. B., Favorskaya I. A., Zrelkin D. I., Voronina D. V., Shcherbinin D. N., Semikhin A. S., Simakova Y. V., Tokarskaya E. A., Egorova D. A., Shmarov M. M., Nikitenko N. A., Gushchin V. A., Smolyarchuk E. A., Zyryanov S. K., Borisevich S. V., Naroditsky B. S., Gintsburg A. L. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia // The Lancet. 2021. Vol. 397, no. 10275. P. 671–681. https://doi.org/10.1016/S0140-6736(21)00234-8
Литература
Popova A. Yu., Ezhlova E. B., Melnikova A. A., Kutyrev V. V., Kozhanova O. I., Cherkasskaya T. S., Lyalina V. I., Smirnov V. S., Bugorkova S. A., Portenko S. A., Naydenova E. V., Shcherbakova S. A., Lomonosova V. I., Totolyan A. A. Characteristics of population immunity to SARS-COV-2 in residents of Saratov and the Saratov region during the COVID-19 epidemic. Problemy osobo opasnykh infektsii,2020, no. 4, pp. 106–116. (In Russian)
Ashby B., Best A. Herdimmunity. Curr. Biol., 2021, vol. 31, no. 4, pp. 174–177.
Borisova A. A., Popova N. D., Kychkina A. I., Rozhina A. A., Fedulova A. G. Epidemiological features of the dynamics of a new coronavirus infection (COVID-19) in the Republic of Sakha (Yakutia). Mezhdunarodnyi nauchno-issledovatel’skii zhurnal, 2022, vol. 1, no. 2, pp. 84–87. (In Russian)
Onishchenko G. G., Sizikova T. E., Lebedev V. N., Borisevich S. V. Comparative characteristics of vaccines against COVID-19 used in mass immunization. BIOpreparaty. Profilaktika, diagnostika, lechenie,2021, vol. 21, no. 3, pp. 158–166. https://doi.org/10.30895/2221-996X-2021-21-3-158-166 (In Russian)
Tsygankov P., Alnikin A. B., Kvashe I. V., Shlyk S. V., Kharseeva G. G., Ryabtseva O. A., Tarabanova I. V. The frequency of detection of positive markers of COVID-19 in individuals with different vaccination history. Epidemiologiia i vaktsinoprofilaktika, 2021, vol. 20, no. 3, pp. 4–7. (In Russian)
Popova A. Iu., Ezhlova E. B., Mel’nikova A. A., Bashketova N. S., Fridman R. K., Lialina L. V., Smirnov V. S., Chkhindzheriia I. G., Grechaninova T. A., Agapov K. A., Arsent’eva N. A., Bazhenova N. A., Batsunov O. K., Danilova E. M., Zueva E. V., Komkova D. V., Kuznetsova R. N., Liubimova N. E., Markova A. N., Khamitova I. V., Lomonosova V. I., Vetrov V. V., Milichkina A. M., Dedkov V. G., Totolian A. A. Population immunity to SARS-CoV-2 among the population of St Petersburg during the COVID-19 epidemic. Problemy osobo opasnykh infektsii, 2020, no. 3, pp. 124–130.(In Russian)
Godkov M. A., Shustov V. V., Korshunov V. A., Stepanov F. S., Bazhenov A. I. Formation of herd immunity to SARS-CoV-2 in the Moscow population. Epidemiologiia i vaktsinoprofilaktika, 2022, vol. 21,no. 1, pp. 81–91. https://doi.org/10.31631/2073-3046-2022-21-1-81-91 (In Russian)
Kadkhoda K. Herd Immunity to COVID-19. Am. J. Clin. Path., 2021, vol. 155, no. 4, pp. 471–472.
Fontanet A., Cauchemez S. COVID-19 herd immunity: Where are we? Nat. Rev. Immunol., 2020,vol. 20, no. 10, pp. 583–584. https://doi.org/10.1038/s41577-020-00451-5
Mellet J., Pepper M. S. A COVID-19 Vaccine: Big Strides Come with Big Challenges. Vaccines (Basel),2021, vol. 9, no. 1, p. 39. https://doi.org/10.3390/vaccines9010039
Mistry P., Barmania F., Mellet J., Peta K., Strydom A., Viljoen I. M., James W., Gordon S., Pepper M. S.SARS-CoV-2 Variants, Vaccines, and Host Immunity. Front. Immunol., 2022, no. 12, p. 809244. https://doi.org/10.3389/fimmu.2021.809244
Lea C. S., Simeonsson K., Kipp A. M., McNeill Ch., Wilcox L., Irish W., Morris H., Diaz O. M., Fallon J. T., Roper R. L. Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months. Vaccines (Basel) 2022, vol. 10, no. 9, p. 1532. https://doi.org/10.3390/vaccines10091532
Popova A. Y., Ezhlova E. B., Melnikova A. A., Patyashina M. A., Sizova E. P., Uzlibaeva L. R., Lyalina L. V., Smirnov V. S., Badamshina G. G., Goncharova A. V., Arbuzova T. V., Lomonosova V. I., Totolyan A. A. Distribution of SARS-CоV-2 seroprevalence among residents of the Republic of Tatarstan during the COVID-19 epidemic period. Zhurnal mikrobiologii, epidemiologii i immunobiologii, 2020,vol. 97, no. 6, pp. 518–528. (In Russian)
Long Q. X., Liu B. Z., Deng H. J., Wu G. C., Deng K., Chen Y. K., Liao P., Qiu J. F., Lin Y., Cai X. F.,Wang D. Q., Hu Y., Ren J. H., Tang N., Xu Y. Y., Yu L. H., Mo Z., Gong F., Zhang X. L., Tian W. G.,Hu L., Zhang X. X., Xiang J. L., Du H. X., Liu H. W., Lang C. H., Luo X. H., Wu S. B., Cui X. P., Zhou Z.,Zhu M. M., Wang J., Xue C. J., Li X. F., Wang L., Li Z. J., Wang K., Niu C. C., Yang Q. J., Tang X. J.,Zhang Y., Liu X. M., Li J. J., Zhang D. C., Zhang F., Liu P., Yuan J., Li Q., Hu J. L., Chen J., Huang A. L.Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med., 2020, vol. 26, no. 6,pp. 845–848.
Dan J. M., Mateus J., Kato Y., Hastie K. M., Yu E. D., Faliti C. E., Grifoni A., Ramirez S. I., Haupt S., Crotty Sh. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science,2021, vol. 371, no. 6529. https://doi.org/10.1126/science.abf4063
Pollan M., Perez-Gjmez B., Pastor-Barriuso R., Oteo J., Hernan M. A., Perez-Olmeda M., Sanmartin J. L., Fernandez-Garcia A., Cruz I., Fernandez de Larrea N., Molina M., Rodriguez-Cabrera F., Martin M., Merino-Amador P., Leon Paniagua J., Munoz-Montalvo J. F., Blanco F., Yotti R. ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): A nationwide, population-based seroepidemiological study. The Lancet, 2020, vol. 396, no. 10250, pp. 535–544. https://doi.org/10.1016/S0140-6736(20)31483-5
Wajnberg A., Amanat F., Firpo A., Altman D. R., Bailey M. J., Mansour M., McMahon M., Meade P., Mendu D. R., Muellers K., Stadlbauer D., Stone K., Strohmeier S., Simon V., Aberg J., Reich D. L., Krammer F., Cordon-Cardo C. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science,2020, vol. 370, no. 6521, pp. 1227–1230. https://doi.org/10.1126/science.abd7728
Van Elslande J., Oyaert M., Ailliet S., Van Ranst M., Lorent N., Vande Weygaerde Y., Andre E., Lagrou K., Vandendriessche S., Vermeersch P. Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infection. J. Clin. Virol., 2021, vol. 136.https://doi.org/10.1016/j.jcv.2021.104765
Kim P., Gordon S. M., Sheehan M. M., Rothberg M. B. Duration of Severe Acute Respiratory Syndrome Coronavirus 2 Natural Immunity and Protection against the Delta Variant: A Retrospective Cohort Study. Clinical Infectious Diseases, 2022, vol. 75, no. 1, pp. e185–e190. https://doi.org/10.1093/cid/ciab999
Lumley S. F., O’Donnell D., Stoesser N. E., Matthews P. C., Howarth A., Hatch S. B., Marsden B. D., Cox S., James T., Warren F., Peck L. J., Ritter T. G., de Toledo Z., Warren L., Axten D., Cornall R. J., Jones E. Y., Stuart D. I., Screaton G., Ebner D., Hoosdally S., Chand M., Crook D. W., O’Donnell A. M., Conlon C. P., Pouwels K. B., Walker A. S., Peto T. E. A., Hopkins S., Walker T. M., Jeffery K., Eyre D. W. Oxford University Hospitals Staff Testing Group. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N. Engl. J. Med., 2021, vol. 384, no. 6, pp. 533–540. https://doi.org/10.1056/NEJMoa2034545
Ibarrondo F. J., Fulcher J. A., Goodman-Meza D., Elliott J., Hofmann C., Hausner M. A., Ferbas K. G., Tobin N. H., Aldrovandi G. M., Yang O. O. Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild COVID-19. N. Engl. J. Med., 2020, vol. 383, no. 11, pp. 1085–1087. https://doi.org/10.1056/NEJMc2025179
Lea C. S., Simeonsson K., Kipp A. M., McNeill C., Wilcox L., Irish W., Morris H., Diaz O. M., Fallon J. T., Roper R. L. Waning of SARS-CoV-2 Seropositivity among Healthy Young Adults over Seven Months. Vaccines (Basel), 2022, vol. 10, no. 9, p. 1532. https://doi.org/10.3390/vaccines10091532
Patel M. M., Thornburg N. J., Stubblefield W. B., Talbot H. K., Coughlin M. M., Feldstein L. R., Self W. H. Change in Antibodies to SARS-CoV-2 over 60 Days among Health Care Personnel in Nashville, Tennessee. JAMA, 2020, vol. 324, no. 17, pp. 1781–1782. https://doi.org/10.1001/jama.2020.18796
Wajnberg A., Mansour M., Leven E., Bouvier N. M., Patel G., Firpo-Betancourt A., Mendu R., Jhang J., Arinsburg S., Gitman M., Houldsworth J., Sordillo E., Paniz-Mondolfi A., Baine I., Simon V., Aberg J., Krammer F., Reich D., Cordon-Cardo C. Humoral response and PCR positivity in patients with COVID-19 in the New York City region, USA: An observational study. Lancet Microbe, 2020, vol. 1, no. 7, pp. E283–E289.https://doi.org/10.1016/S2666-5247(20)30120-8
Logunov D. Y., Dolzhikova I. V., Shcheblyakov D. V., Tukhvatulin A. I., Zubkova O. V., Dzharullaeva A. S., Kovyrshina A. V., Lubenets N. L., Grousova D. M., Erokhova A. S., Botikov A. G., Izhaeva F. M., Popova O., Ozharovskaya T. A., Esmagambetov I. B., Favorskaya I. A., Zrelkin D. I., Voronina D. V., Shcherbinin D. N., Semikhin A. S., Simakova Y. V., Tokarskaya E. A., Egorova D. A., Shmarov M. M., Nikitenko N. A., Gushchin V. A., Smolyarchuk E. A., Zyryanov S. K., Borisevich S. V., Naroditsky B. S., Gintsburg A. L. Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomized controlled phase 3 trial in Russia. The Lancet, 2021, vol. 397, no. 10275, pp. 671–681. https://doi.org/10.1016/S0140-6736(21)00234-8
Downloads
Published
2023-03-27
How to Cite
Tovanova , A. (2023). Creation of collective immune as the main preventive measure for the spread of the new coronavirus infection (COVID-19). Vestnik of Saint Petersburg University. Medicine, 17(3), 212–220. https://doi.org/10.21638/spbu11.2022.306
Issue
Section
Epidemiology
License
Articles of "Vestnik of Saint Petersburg University. Medicine" are open access distributed under the terms of the License Agreement with Saint Petersburg State University, which permits to the authors unrestricted distribution and self-archiving free of charge.
